Burmester GR, et al. - This study entailed the illustration of the long-term safety and efficacy of mavrilimumab in rheumatoid arthritis patients in two phase IIb studies (1071, 1107) and open-label extension study. The inference drawn was that long-term treatment with mavrilimumab maintained response and was well-tolerated with no increase in TEAE incidence. Findings demonstrated comparable safety data among both phase IIb qualifying studies.